Filana THERAPEUTICS, Inc. (FLNA) intrinsic value & 10-year financials
Filana THERAPEUTICS, Inc. (FLNA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.70
- Market cap
- $34.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -170.0%
- Free cash flow (FY2025)
- -$32.8M
FLNA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$91.0M | -$1.88 | -$32.8M | — | -86.7% |
| FY2024 | — | -$24.3M | -$1.46 | -$117.0M | — | -866.1% |
| FY2023 | — | -$97.2M | -$2.32 | -$82.4M | — | -453.3% |
| FY2022 | — | -$76.2M | -$1.90 | -$80.2M | — | -323.2% |
| FY2021 | — | -$32.4M | — | -$52.4M | — | -331.4% |
| FY2020 | — | -$6.3M | — | — | — | 591.4% |
| FY2019 | — | -$4.6M | — | -$2.5M | — | -22.2% |
| FY2018 | — | -$6.6M | — | — | — | -44.7% |
| FY2017 | — | -$11.9M | — | — | — | -84.1% |
| FY2016 | — | -$14.8M | — | -$12.3M | — | -79.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
FILANA THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
FILANA THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -33.1% ROIC.
FILANA THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
FILANA THERAPEUTICS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.